Published in Medical Patent Law Weekly, August 10th, 2005
This patent covers compositions of matter for the NRG2 family of growth factors as well as methods of production for NRG2. The addition of this patent broadens Acorda's existing neuregulin portfolio. NRG2 has potential applications in multiple sclerosis, spinal cord injury, Parkinson disease and chronic heart failure. The company plans to continue to file patents in support of the neuregulins program.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.